Terazosin for treating symptomatic benign prostatic obstruction: A systematic review of efficacy and adverse effects

BJU International

Volumn 89, Issue 3, 2002, Pages 214-225

  Wilt, T J ^a   Howe, W ^b   MacDonald, R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Lostwithiel Medical Practice   (United Kingdom)

Author keywords

BPH; Lower urinary tract symptoms; Systematic review; Terazosin; 1 adrenoceptor antagonists

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; PLACEBO; PRAZOSIN; TAMSULOSIN; TERAZOSIN;

ADULT; AGE; AGED; ARTICLE; ASTHENIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG WITHDRAWAL; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROWAVE IRRADIATION; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RACE DIFFERENCE; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME; URINARY TRACT OBSTRUCTION; URINE FLOW RATE; VERTIGO;

EID: 0036175103     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-4096.2001.02537.x-i1     Document Type: Article

References (47)

1. The development of human benign prostatic hyperplasia with age
2. Impact of previously unrecognised benign prostatic hyperplasia on the daily activities of middle aged and elderly men
3. Transurethral prostatectomy. Practice aspects of the dominant operation in American urology
4. A nationwide survey of practicing urologists: Current management of benign prostatic hyperplasia and clinically localized prostate cancer
5. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review
6. Drug treatment for benign prostatic hyperplasia. Health authorities must audit use of finasteride
7. Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: Past, present and future
8. Identifying relevant studies for systematic reviews
9. Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
10. Terazosin in the treatment of benign prostatic hyperplasia
11. The international terazosin trial. A multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia
12. Use of terazosin in the medical treatment of benign prostatic hyperplasia: Experience in Italy
13. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia
14. Efficacy of once-a-day terazosin in benign prostatic hyperplasia: A randomized, double-blind placebo-controlled clinical trial
15. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia
16. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
17. Terazosin in the treatment of benign prostatic hyperplasla: A multicentre, placebo-controlled trial
18. The Hytrin Community Assessment Trial study, a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group
19. Terazosin for the treatment of benign prostatic hyperplasia in the elderly: A 6-month double-blind study
20. Clinical comparison of selective and nonselective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses
21. Clinical comparison of selective and non-selective alpha 1A-adrenocepinr antagonists for bladder outlet obstruction associated with benign prostatic hyperplasla: Studies on tamsulosin and terazosin in Chinese patients
22. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients
23. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: A short-term open, randomized multicenter studyBPH medical therapy study group. Benign prostatic hyperplasia
24. Efficiency and tolerance of terazosin in ambulatory patients with benign prostatic hypertrophy: Comparative randomized and double-blind trial versus alfuzosin
25. Terazosin and doxazosin in normotensive men with symptomatic prostatism: A pilot study to determine the effect of dosing regimen on efficacy and safety
26. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia
27. Clinical experience. Symptomatic management af BPH with terazosin
28. Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: A primary care trial
29. The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia
30. The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH
31. A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia
32. Efficacy of terazosin in patients with benign prostatic hyperplasia
33. A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy
34. Patterns of use of terazosine in current medical practice in ambulatory patients with obstructive and irritative obstructive disorders of urination
35. Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia
36. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing
37. Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin
38. Effect of finasteride and/or terazosin on serum PSA. Results of VA cooperative study 359
39. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications
40. Terazosin in benign prostatic hyperplasia, effects on blood pressure in normotensive and hypertensive men
41. Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin
42. Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up
43. The mechanism of adverse events associated with terazosin: An analysis of the veterans affairs cooperative study
44. Treatment of benign prostatic hyperplasia
45. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists inpatients with lower urinary tract symptums suggestive of benign prostatic obstruction
46. Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement
47. Improving the quality of reporting of randomized controlled trials: The CONSORT statement